July 24th 2024
Margins < 1 mm also do not increase the risk of cutaneous squamous cell carcinoma recurrence risk if the galea aponeurotica is not involved.
Frontline Forum Part 4: Improving Basal Cell Carcinoma Management
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
Frontline Forum Part 3: Improving Basal Cell Carcinoma Management
In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.
Frontline Forum Part 2: Improving Basal Cell Carcinoma Management
In part 2 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.
Frontline Forum Part 1: Improving Basal Cell Carcinoma Management
In part 1 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.
SLIDESHOW: Highlights from the 2023 American College of Mohs Surgery Meeting
May 11th 2023Catch up on the innovative pearls shared at the 2023 American College of Mohs Surgery including strategies to enhace the patient experience, the role artificial intelligence plays in dermatologic care, and more.